Additional Hetero Ring Containing Patents (Class 549/59)
-
Publication number: 20120283222Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.Type: ApplicationFiled: May 31, 2012Publication date: November 8, 2012Applicant: Ajinomoto Co., Inc.Inventors: Atsushi KONISHI, Munetaka Tokumasu, Tamotsu Suzuki, Takahiro Koshiba, Koji Ohsumi, Osamu Ikehara, Yuko Kodama
-
Patent number: 8299272Abstract: It is an object of the present invention to provide a method for manufacturing a fused ring compound, with which a fused ring compound that has excellent charge transport property and that has excellent solubility in solvents can be obtained efficiently.Type: GrantFiled: March 9, 2007Date of Patent: October 30, 2012Assignee: Sumitomo Chemical Company, LimitedInventors: Masahiro Miura, Tetsuya Satoh, Hiroyuki Watanabe, Masato Ueda
-
Patent number: 8288380Abstract: A compound of formula (1): wherein R1 and R2 represent hydrogen, lower alkyl, lower alkenyl, lower alkynyl or R3 represents hydroxyl, lower alkoxy, lower cycloalkyloxy, aryloxy, carboxy, lower alkoxycarbonyl, or NRaRb of the formula R4 and R5 represent halogen, lower alkyl, hydroxyl, or lower alkoxy; R6 represents halogen, lower alkyl, aryl, heterocyclic, hydroxy, lower alkoxy, mercapto, lower alkylthio, lower alkylcarbonyl, amino, nitro or cyano; R7 represents lower alkyl, hydroxyl or lower alkoxy; Ra and Rb represent hydrogen or lower alkyl; ring A represents a cyclic hydrocarbon or a heterocyclic ring; ring B represents a heterocyclic ring; X represents lower alkylene; Z represents a single bond or lower alkylene; Y represents lower alkylene and W1—W2 represents CH—CH, or Y represents a single bond and W1—W2 represents N—CH, CH—N or CH—CH; and 1, m, n and o represent 0, 1, 2, or 3.Type: GrantFiled: April 17, 2012Date of Patent: October 16, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Mogi, Hisashi Tajima, Noriko Mishina, Yusuke Yamazaki, Shinji Yoneda, Katsuhiko Watanabe, Junko Fujikawa, Minoru Yamamoto
-
Publication number: 20120241004Abstract: The present invention relates to the technical field of organic materials. Thiophene-containing organic photoelectric materials are provided, which comprise compounds shown by structural formula (1), wherein R1, R2, R3 and R4 are the same or different and represent hydrogen or straight, branched or cyclic alkyl containing 1 to 12 carbon atoms, m, n and p are the same or different integer between 0 and 6. Preparation methods of these thiophene-containing organic photoelectric materials and solar cell devices containing the above thiophene-containing organic photoelectric materials also are provided. Due to the fact that thiophene rings and cyano groups are included, the above thiophene-containing organic photoelectric materials have broader spectra respondence, better thermal stability and environmental stability.Type: ApplicationFiled: December 14, 2009Publication date: September 27, 2012Inventors: Minglie Zhou, Jie Huang, Hui Liu
-
Patent number: 8274213Abstract: Disclosed herein are novel electrochromic materials. The electrochromic materials produce various colors and have bistability to achieve red-green-blue full colors. Therefore, the electrochromic materials can be used in a variety of electrochromic devices. Also disclosed herein are electrochromic devices fabricated using the electrochromic materials.Type: GrantFiled: April 13, 2009Date of Patent: September 25, 2012Assignee: Samsung Electronics Co., Ltd.Inventors: Seung Uk Son, Ji Min Lee, Chang Ho Noh
-
Publication number: 20120238569Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.Type: ApplicationFiled: February 17, 2012Publication date: September 20, 2012Inventors: Paul Gillespie, Christophe Michoud, Kenneth Carey Rupert, Kshitij Chhabilbhai Thakkar
-
Publication number: 20120232270Abstract: Disclosed are an oligomer and a phthalonitrile monomer having the formulas: M is a metal or H. The value n is an integer greater than or equal to 1 for the oligomer and greater than or equal to 0 for the phthalonitrile monomer. Ar1 and Ar2 are independently selected aromatic- or heterocyclic-containing groups. Ar1, Ar2, or both are heteroaromatic or heterocyclic groups containing a nitrogen, sulfur, or oxygen heteroatom. Also disclosed are thermosets and pyrolyzed materials made from the phthalonitrile monomer.Type: ApplicationFiled: May 24, 2012Publication date: September 13, 2012Applicant: The Government of the United States of America, as represented by the Secretary of the NavyInventors: Matthew Laskoski, Teddy M. Keller
-
Patent number: 8263788Abstract: The invention relates to a method for producing 1,3-dioxolane-2-ones of general formula (3) in basic reaction conditions by reesterifying the respective ester of general formula (1) in which R1 to R5 have the meanings indicated in the claims and the description. The invention further relates to a method for producing 2-hydroxy carboxylic acid esters of general formula (5) with or without isolation of the intermediate in the form of a derivative of the 1,3-dioxolane-2-one of general formula (3) in basic reaction conditions by reesterifying the respective ester of general formula (1) in which R1, R2, and R6 have the meanings indicated in the claims and the description. The method according to the invention allows the reaction to take place in very gentle basic conditions, causing fewer secondary reactions and providing a greater yield than reactions in highly polar aprotic solvents. Acid-sensitive and/or temperature-sensitive compounds can be synthesized.Type: GrantFiled: September 3, 2008Date of Patent: September 11, 2012Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Joerg Brandenburg, Rolf Dach, Hanfried Baltes
-
Publication number: 20120205596Abstract: The present invention provides a macromolecular compound by which the short-circuit current density and the photoelectric conversion efficiency are enhanced when the macromolecular compound is used in an organic layer contained in a photovoltaic cell.Type: ApplicationFiled: October 29, 2010Publication date: August 16, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Ken Yoshimura, Kenichiro Ohya
-
Publication number: 20120203012Abstract: There are provided a heteroaromatic-containing compound represented by the following general formula (1), and an optical material including the heteroaromatic-containing compound. wherein R1 and R2 are each independently a hydrogen atom or a methyl group, Ar1 is an aryl group which may have a substituent, and A is an aromatic hydrocarbon group. The R1 and R2 can be a hydrogen atom, and Ar1 can be a phenyl group.Type: ApplicationFiled: December 16, 2010Publication date: August 9, 2012Applicant: CANON KABUSHIKI KAISHAInventor: Terunobu Saitoh
-
Patent number: 8236968Abstract: The present invention relates to novel 1,4-bis(2-thienylvinyl)benzene derivatives, to conjugated polymers, dendrimers, blends, mixtures and formulations comprising same, and to the use thereof in electronic devices, in particular in polymeric organic light-emitting diodes.Type: GrantFiled: July 5, 2007Date of Patent: August 7, 2012Assignee: Merck Patent GmbHInventors: Arne Buesing, Susanne Heun, Aurélie Ludemann, Frank Egon Meyer, Niels Schulte
-
Patent number: 8222288Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).Type: GrantFiled: June 14, 2010Date of Patent: July 17, 2012Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Dongguang Qin, Jianyong Chen, Shanghai Yu
-
Patent number: 8221903Abstract: The invention pertains to new materials based on donor carbene intermediates for the improvement of electron injection and electron transport in organic electronic components like organic light-emitting diodes (OLED's), organic field effect transistors (OFET's), and components based on organic photovoltaics, in particular organic solar cells.Type: GrantFiled: August 29, 2006Date of Patent: July 17, 2012Assignee: Osram Opto Semiconductors GmbHInventor: Andreas Kanitz
-
Publication number: 20120178780Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.Type: ApplicationFiled: March 19, 2012Publication date: July 12, 2012Inventors: Jill E. WOOD, Hanno Wild, Daniel H. Rogers, John Lyons, Michael Katz, Yolanda Caringal, Robert Dally, Wendy Lee, Roger A. Smith, Cheri Blum
-
Patent number: 8216768Abstract: A photoacid generator, which shows very high sensitivity in the near ultraviolet range of about 300 to 400 nm, and also can remarkably increase a reaction rate of a photoreactive composition using the same, and a photoreactive composition which can initiate the reaction even by irradiation with near ultraviolet light within a short time and also can obtain a desired reaction product.Type: GrantFiled: October 30, 2008Date of Patent: July 10, 2012Assignee: Sumitomo Seika Chemicals Co., Ltd.Inventors: Katsumasa Yamamoto, Hirofumi Yamaguchi, Michio Suzuki
-
Publication number: 20120171111Abstract: The present invention provides a process for producing an oxidation reaction product of an aromatic compound, having excellent environmental load reduction performance, cost reduction performance, etc. Provided is a process for producing an oxidation reaction product of a raw material aromatic compound by reacting the raw material aromatic compound with an oxidizing agent. The process further uses an electron donor-acceptor linked molecule. The process includes the step of: reacting the electron donor-acceptor linked molecule in an electron-transfer state, the oxidizing agent, and the raw material aromatic compound, thereby generating an oxidation reaction product resulting from oxidation of the raw material aromatic compound.Type: ApplicationFiled: September 15, 2010Publication date: July 5, 2012Applicant: OSAKA UNIVERSITYInventors: Kei Ohkubo, Shunichi Fukuzumi, Kentaro Mizushima
-
Publication number: 20120153265Abstract: The present invention relates to solid solution inducing layer for the preparation of weak epitaxial films of non-planar phthalocyanine and the thin film of non-planar phthalocyanine generated from the weak epitaxial growth on the solid solution inducing layer and organic thin film transistor based on the weak rpitaxy growth thin film of non-planar phthalocyanine. The solid solution inducing layer is prepared at certain substrate temperature by vapor co-deposition of any two inducing layer molecules presented by Formula I and Formula II. The solid solution inducing layer has uniformed structure, of which the lattice parameter and electronic structure can be controlled by adjusting the component proportion, the solid solution inducing layer can epitaxially grow a high quality thin film of non-planar phthalocyanine and fabricate high performance transistor device based on such epitaxial thin film.Type: ApplicationFiled: July 20, 2011Publication date: June 21, 2012Inventors: Donghang YAN, Yanhou Geng, Hongkun Tian, Lizhen Huang, Jianfeng Shen, Xiaodong Guo
-
Publication number: 20120153815Abstract: A material for an organic electroluminescence device having the formula: wherein Ar1 and Ar3 each independently represent a substituted or unsubstituted phenylene group, X5 represents a substituted or unsubstituted naphthyl group or a substituted or unsubstituted phenanthryl group, X6 represents a substituted or unsubstituted phenyl group, and X7 and X8 each independently represent a substituted or unsubstituted biphenyl group or a substituted or unsubstituted terphenyl group. An organic electroluminescence device having (i) a light emitting layer, or (ii) a plurality of thin films of organic compounds having a light emitting layer, disposed between a pair of electrodes, wherein at least one of the thin films of organic compounds is a layer containing the material having the formula above.Type: ApplicationFiled: January 31, 2012Publication date: June 21, 2012Applicant: Idemitsu Kosan Co., Ltd.Inventors: Chishio Hosokawa, Masakazu Funahashi, Hisayuki Kawamura, Hiromasa Arai, Hidetoshi Koga, Hidetsugu Ikeda
-
Publication number: 20120157516Abstract: The present invention relates to novel substituted thiophene derivatives useful in therapy of diseases related to misfolded and aggregated proteins.Type: ApplicationFiled: October 19, 2009Publication date: June 21, 2012Inventors: Peter Åsberg, Leif Johansson, Anna Herland, Andreas Åslund, Peter Konradsson
-
Patent number: 8198271Abstract: A compound having the following formula (1) or a salt thereof: wherein R1 and R2 represent hydrogen, a lower alkyl, a lower alkenyl, a lower alkynyl or a group having the following formula (2): (R6)n—{circle around (A)}—Z—??(2), R3 represents hydroxy, a lower alkoxy, a lower cycloalkyloxy, an aryloxy, carboxy, a lower alkoxycarbonyl, or —NRaRb having the following formula (3): (R7)o—{circle around (B)}—??(3), R4 and R5 represent halogen, a lower alkyl, hydroxy, or a lower alkoxy; R6 represents halogen, a lower alkyl, an aryl group, a heterocyclic, a hydroxy, a lower alkoxy, mercapto, a lower alkylthio, a lower alkylcarbonyl, amino, nitro or cyano; R7 represents a lower alkyl, hydroxy or a lower alkoxy; Ra and Rb represent hydrogen or a lower alkyl; the ring A represents a cyclic hydrocarbon or a heterocyclic ring; the ring B represents a heterocyclic ring having one or more heteroatoms selected from the group consisting of nitrogen and oxygen; X represents a lower alkylene; Y represents a lower alkyleType: GrantFiled: May 25, 2009Date of Patent: June 12, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Mogi, Hisashi Tajima, Noriko Mishina, Yusuke Yamazaki, Shinji Yoneda, Katsuhiko Watanabe, Junko Fujikawa, Minoru Yamamoto
-
Patent number: 8197722Abstract: Compositions capable of simultaneous two-photon absorption and higher order absorptivities are provided. Compounds having a donor-pi-donor or acceptor-pi-acceptor structure are of particular interest, where the donor is an electron donating group, acceptor is an electron accepting group, and pi is a pi bridge linking the donor and/or acceptor groups. The pi bridge may additionally be substituted with electron donating or withdrawing groups to alter the absorptive wavelength of the structure. Also disclosed are methods of generating an excited state of such compounds through optical stimulation with light using simultaneous absorption of photons of energies individually insufficient to achieve an excited state of the compound, but capable of doing so upon simultaneous absorption of two or more such photons. Applications employing such methods are also provided, including controlled polymerization achieved through focusing of the light source(s) used.Type: GrantFiled: July 30, 2001Date of Patent: June 12, 2012Assignee: The California Institute of TechnologyInventors: Seth Marder, Joseph Perry
-
Publication number: 20120142855Abstract: The present invention relates to polymers comprising structural units having partially fluorinated substituents, to mixtures and formulations comprising the polymers according to the invention, to a process for the preparation of the polymers according to the invention, and to the use of the polymers according to the invention as functional materials in electronic devices.Type: ApplicationFiled: June 24, 2010Publication date: June 7, 2012Applicant: Merck Patent GmbH Patents & Scientific InformationInventors: René P. Scheurich, Junyou Pan, Frank Egon Meyer, Niels Schulte, Rémi Manouk Anèmian, Susanne Heun, Thomas Eberle, Aurélie Ludemann, Herwig Buchholz, Wolfgang Hierse
-
Patent number: 8193187Abstract: The compounds represented in general formula (1) or a salt thereof are useful for glucocorticoid receptor modulators. In the formula, R1 represents a lower alkyl group, a lower cycloalkyl group, an aryl group and the like; R2 represents a hydrogen atom, a lower alkyl group and the like; R3 represents a hydrogen atom, a lower alkyl group and the like; R4 and R5 represent a hydrogen atom, a lower alkyl group and the like; R6 represents a hydrogen atom, a lower alkyl group and the like; R7 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group and the like; W represents an oxygen atom, a sulfur atom, NR8 and the like; R8 represents a hydrogen atom, a lower alkyl group and the like; X represents an oxygen atom or a sulfur atom; Y represents a lower alkylene group and the like; Z represents an oxygen atom, a sulfur atom, NR9, OCO or OSO2; R9 represents a hydrogen atom, a lower alkyl group and the like respectively.Type: GrantFiled: May 29, 2008Date of Patent: June 5, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Mamoru Matsuda, Toshiyuki Mori, Masato Nagatsuka, Sachiko Kobayashi, Masatomo Kato, Miwa Takai
-
Publication number: 20120128640Abstract: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.Type: ApplicationFiled: June 4, 2010Publication date: May 24, 2012Applicant: NISSAN CHEMICAL INDUSTRIES LTD.Inventors: Taito Nishino, Shunsuke Iwamoto, Katsuaki Miyaji
-
Patent number: 8183390Abstract: The invention demonstrates the synthesis of a new pyrazole-containing monomer by means of an easily implemented two-step process. This monomer can be electropolymerized to yield a stable n-doping polymer that may easily be electrochemically characterized. It is demonstrated that the electrochemical behavior of the polymer films produced is dependent upon the conditions applied during electrodeposition. Films deposited by cycling only at relatively positive potentials (0 to 2000 mV) show less intense n-doping responses than those films obtained by scanning the applied potential throughout a wider range (?2000 mV to 2000 mV).Type: GrantFiled: August 18, 2010Date of Patent: May 22, 2012Assignee: The United States of America as represented by the Secretary of the NavyInventors: David J. Irvin, David L. Witker, John D. Stenger-Smith, Jennifer A. Irvin
-
Patent number: 8183560Abstract: The present invention provides a light emitting device comprising at least an emissive layer existing between an anode and a cathode, which emits light by means of electric energy. The light emitting device contains a compound having a pyrromethene skeletal structure with a specific structure or a metal complex thereof and a naphthacene derivative, and thus the light emitting device has high luminance efficiency and excellent durability.Type: GrantFiled: October 15, 2007Date of Patent: May 22, 2012Assignee: TORAY Industries, Inc.Inventors: Takeshi Ikeda, Tsuyoshi Tominaga, Kazunori Sugimoto, Kazumasa Nagao
-
Patent number: 8178535Abstract: Substituted sulfonamide compounds corresponding to the formula I? wherein m, n, p, X, Y, Z, R1, RA and RB have specified meanings, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these substituted sulfonamide compounds for the treatment and/or inhibition of pain or other conditions.Type: GrantFiled: January 16, 2009Date of Patent: May 15, 2012Assignee: Gruenenthal GmbHInventors: Beatrix Merla, Stefan Oberboersch, Ruth Jostock, Michael Engels, Stefan Schunk, Melanie Reich, Sabine Hees
-
Patent number: 8178556Abstract: Described are pyridopyrazinone derivatives of formula (I), wherein X, Y, Z, W, A and R1 are as defined in claim 1, as insulin secretion stimulators. Also described is the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.Type: GrantFiled: February 27, 2009Date of Patent: May 15, 2012Assignee: Merck Patent Gesellschaft MIT Beschraenkter HaftungInventors: Gerard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
-
Publication number: 20120115915Abstract: Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N?-diarylureas and/or N,N?-diarylthiourea compounds are described.Type: ApplicationFiled: May 28, 2010Publication date: May 10, 2012Applicant: President and Fellows of Harvard CollegeInventors: Bertal Huseyin Aktas, José A. Halperin, Michael Chorev
-
Publication number: 20120108636Abstract: The present invention provides compounds of formula (I) wherein W, R1, R5 and R6 have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric enhancers of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain, and inflammatory pain, cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke, neurological disease or injury, sleep disorders, epilepsy and depression.Type: ApplicationFiled: January 11, 2012Publication date: May 3, 2012Inventors: Pier Giovanni Baraldi, Allan R. Moorman, Romeo Romagnoli
-
Publication number: 20120095012Abstract: The present invention provides compounds of formula (I), wherein R1 is a monocyclic 5- or 6-membered heteroaryl; R4 is phenyl or monocyclic 5- or 6-membered heteroaryl; and the other substituents as defined in the claims, that inhibit cell and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)—mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders.Type: ApplicationFiled: December 30, 2009Publication date: April 19, 2012Applicant: Elara Pharmaceuticals GmbHInventors: Jorge Alonson, Arantxa Encinas Lopez, Marcel Muelbaier, Jochen Ammenn, Bernd Wendt, Joe Lewis, Christoph Schultes, Bernd Janssen
-
Patent number: 8153822Abstract: A fluorene compound is provided, which is represented by the following Formula (I): in Formula (1), R11 and R12 each independently represent an alkyl group having 1 to 6 carbon atoms; R21 and R22 each independently represent an alkyl group having 1 to 8 carbon atoms, or an alkoxy group having 1 to 8 carbon atoms; and n1 and n2 each independently represent an integer of from 1 to 5.Type: GrantFiled: September 2, 2009Date of Patent: April 10, 2012Assignee: Fuji Xerox Co., Ltd.Inventors: Hidekazu Hirose, Koji Horiba, Akira Imai, Takeshi Agata, Katsuhiro Sato
-
Patent number: 8154787Abstract: Green electrochromic (EC) materials based on thiophene, and a green EC material based on pyrazine are disclosed. A first thiophene derivative (2,3-Di-thiophen-2-yl-thieno[3,4-b]pyrazine), which was previously investigated as a nonlinear optical material, is here disclosed for its use as an EC material and for its incorporation into an EC device. Synthesis of two new thiophene derivatives (2,5-di(thien-2-yl)-3,4-di(2,2,2-trifluoro-ethoxy)-thiophene and 2,5-(2,3-dihydro-thieno[3,4-b][1,4]dioxin-5-yl)-3,4-di(2,2,2-trifluoro-ethoxy)-thiophene), and a new pyrazine derivative (2,3-dibenzyl-5,7-di(thien-2-yl) thieno[3,4-b]pyrazine) are also disclosed, since these materials are all able to selectively change state to appear a green color and can be polymerized to achieve a green EC polymer.Type: GrantFiled: August 27, 2010Date of Patent: April 10, 2012Assignee: University of WashingtonInventors: Lu Liu, Chunye Xu, Minoru Taya
-
Patent number: 8148410Abstract: The invention relates to novel thiophene derivatives (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I).Type: GrantFiled: December 9, 2008Date of Patent: April 3, 2012Assignee: Actelion Pharmaceuticals Ltd.Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner
-
Patent number: 8148408Abstract: The present application describes selective ligands of formula (I) for neuronal nicotinic receptors (NNRs), more specifically for the ?4?2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.Type: GrantFiled: April 27, 2009Date of Patent: April 3, 2012Assignee: Abbott LaboratoriesInventors: William H. Bunnelle, Lei Shi, Marc J. C. Scanio
-
Publication number: 20120067742Abstract: The present invention provides a linker for joining an electrode and a capture probe on a biochip, and a biochip comprising the linker. The impedance baseline of the linker of the present invention is three orders lower than the conventional long chain thiol linker when adopting in a fadaraic impedance biochip construction. With lower impedance baseline, the device designed to measure the signal of the biochip of the present invention could be further simplied on the electrical circuit design and be made in lower cost, compacter size and get the potential to be used in point-of-care applications. The present invention also provides a method of quantitatively detecting a concentration of a target analyte in a fluid sample by adopting the biochip and the linker of present invention.Type: ApplicationFiled: June 16, 2011Publication date: March 22, 2012Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Chih-Kung Lee, Adam Shih-Yuan Lee, Ching-Sung Chen, Ku-Ning Chang, Ying-Hua Chen, Bryan Yong-Jay Lee
-
Patent number: 8138189Abstract: The present invention relates to compounds of formula I wherein R.sup.1a to R.sup.1e and R.sup.2 to R.sup.5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.Type: GrantFiled: March 19, 2010Date of Patent: March 20, 2012Assignee: Hoffman-La Roche Inc.Inventors: Daniel Hunziker, Chrisitan Lerner, Werner Mueller, Ulrike Obst Sander, Philippe Pflieger, Pius Waldmeier
-
Publication number: 20120048377Abstract: Photosensitive optoelectronic devices are disclosed including at least one compound comprising at least one polycyclic aromatic substructure wherein the substructures are directly substituted with at least one alkynyl group. The devices exhibit a high degree of stability. In one form the devices may be used in the generation of solar power.Type: ApplicationFiled: March 5, 2010Publication date: March 1, 2012Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONInventors: Kevin Norman Winzenberg, Scott Edward Watkins, Kimmo Petteri Kemppinen, Mark Bown
-
Patent number: 8124606Abstract: Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R11, X, and m are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.Type: GrantFiled: March 4, 2011Date of Patent: February 28, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
-
Publication number: 20120045474Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.Type: ApplicationFiled: August 29, 2011Publication date: February 23, 2012Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
-
Publication number: 20120045720Abstract: A color contrast image in imaged lithographic printing precursors can be obtained by contacting the imaged precursor with a coloration solution containing a colorless form of a photochromic compound. Residual amounts of this compound attached to the oleophilic surface of the imaged precursor can be changed to its colored form when exposed to UV light. The coloration solution can be an alkaline or acidic developer or an alkaline or acidic solution used separately after development. The coloration solution can also be a gum solution.Type: ApplicationFiled: August 20, 2010Publication date: February 23, 2012Inventors: Murray Figov, Ruizheng Wang, Moshe Marom, Ilan Levi, Eynat Matzner
-
Publication number: 20120025183Abstract: Provided is an acenaphtho[1,2-k]benzo[e]acephenanthrene derivative represented by general formula (1): wherein R1 to R16 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group; and at least one of R1 to R8 and R10 to R15 is selected from a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.Type: ApplicationFiled: April 22, 2010Publication date: February 2, 2012Applicant: CANON KABUSHIKI KAISHAInventors: Jun Kamatani, Takayuki Horiuchi, Naoki Yamada, Akihito Saitoh
-
Patent number: 8107150Abstract: Diarylethene-containing ligands and their coordination compounds are described. The ligands display photochromism with UV excitation, while the coordination compounds display photochromism with both excitation in the UV region and excitation into lower energy absorption bands characteristic of the coordination compounds, through which the excitation wavelengths for the photocyclization can be extended from ??340 nm to wavelengths beyond 470 nm. Switching of the luminescence properties of the compounds has also been achieved through photochromic reactions.Type: GrantFiled: January 26, 2010Date of Patent: January 31, 2012Assignee: Versitech LimitedInventors: Vivian Wing-Wah Yam, Chi-Chiu Ko
-
Publication number: 20120022116Abstract: Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject.Type: ApplicationFiled: July 13, 2011Publication date: January 26, 2012Inventors: Huayun Deng, Ye Fang, Mingqian He, Haibei Hu, Weijun Niu, Haiyan Sun
-
Publication number: 20120015911Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: September 20, 2011Publication date: January 19, 2012Applicant: Bellus Health Inc.Inventors: Xianqi Kong, Xinfu Wu, Abderrahim Bouzide, Isabelle Valade, David Migneault, Francine Gervais, Daniel Delorme, Benoit Bachand, Mohamed Atfani, Sophie Levesque, Bita Samim
-
Patent number: 8097694Abstract: Disclosed are organic semiconductor thin films using aromatic enediyne derivatives, manufacturing methods thereof, and methods of fabricating electronic devices incorporating such organic semiconductor thin films. Aromatic enediyne derivatives according to example embodiments provide improved chemical and/or electrical stability which may improve the reliability of the resulting semiconductor devices. Aromatic enediyne derivatives according to example embodiments may also be suitable for deposition on various substrates via solution-based processes, for example, spin coating, at temperatures at or near room temperature to form a coating film that is then heated to form an organic semiconductor thin film. The availability of this reduced temperature processing allows the use of the aromatic enediynes derivatives on large substrate surfaces and/or on substrates not suitable for higher temperature processing.Type: GrantFiled: March 6, 2009Date of Patent: January 17, 2012Assignee: Samsung Electronics Co., Ltd.Inventors: Eun Jeong Jeong, Hyun Sik Moon, Kook Min Han
-
Publication number: 20120010187Abstract: The invention provides FIG. 1 novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative E. coli strains, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram positive bacteria, perhaps involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and in blocking biofilm formation in the nanomolar range; ranges considered are well within the range of utility as therapeutics.Type: ApplicationFiled: March 16, 2010Publication date: January 12, 2012Applicant: University of Virginia Patent FoundationInventors: Paul S. Hoffman, Richard L. Guerrant, Timothy L. Macdonald, Thomas Eric Ballard, JR.
-
Publication number: 20110319446Abstract: Compounds of formula (I) have muscarinic M3 receptor modulating activity; wherein A is an oxygen atom or group —N(R12)—; (i) R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group —R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2 is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3 is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to whiType: ApplicationFiled: June 20, 2011Publication date: December 29, 2011Applicant: Argenta Discovery Ltd.Inventors: Harry Finch, Nicholas Charles Ray, Richard James Bull, Monique Bodil van Niel, Andrew Stephen Robert Jennings
-
Patent number: 8084467Abstract: One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.Type: GrantFiled: June 24, 2005Date of Patent: December 27, 2011Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Qian Liu, Rajesh Thotapally, Venkata Kiran Vemuri
-
Patent number: 8084489Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptor antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising N compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.Type: GrantFiled: February 9, 2006Date of Patent: December 27, 2011Assignee: Eli Lilly and CompanyInventors: Mark Donald Chappell, Scott Eugene Conner, Allie Edward Tripp, Guoxin Zhu